Day: March 17, 2026

VANCOUVER, British Columbia, March 17, 2026 (GLOBE NEWSWIRE) — Refined Energy Corp. (CSE: RUU; OTC: RRUUF; FRA: CWA0) (“Refined” or the “Company”) announces that the first drill hole of its maiden drill program has successfully reached target depth beyond the unconformity at the Dufferin West property, located in Saskatchewan’s prolific Athabasca Basin uranium district. HighlightsMaiden drill hole (DW26-001) successfully reached targeted unconformity depth at 332 metres, validating the Company’s geological model; Second drill hole (DW26-002) now underway testing the same high-priority EM conductor and associated structural target; Ground gravity survey completed to further refine structural drill targets; Initial drill program planned for a minimum of three holes totaling approximately 1,200 metresDrill hole DW26-001 intersected...

PHOENIX, March 17, 2026 (GLOBE NEWSWIRE) — 1606 Corp. (OTC: CBDW) announced that it has executed a Purchase and Sale Agreement to acquire a 132-acre property in Lufkin, Texas that includes an existing power generation facility and infrastructure suitable for large-scale data center development.The property includes approximately 132 acres of land along with improvements, equipment, and associated development rights, making it well positioned for the deployment of data center infrastructure supported by on-site power generation. The property also includes a 50,000-square-foot warehouse designed to support rapid deployment of data center infrastructure, making the site immediately attractive to potential data center operators.Under the terms of the agreement, the total purchase price for the property is approximately $11.2 million,...

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) — Ridgepost Capital, Inc. (NYSE: RPC) (“Ridgepost Capital”), a leading private markets solutions provider, and Enhanced Capital Group, LLC (“Enhanced Capital”), a private credit strategy of Ridgepost Capital, today announced that Enhanced Capital has been selected to the ImpactAssets 50 (“IA 50”) 2026, the definitive guide to impact investing fund managers globally. Now in its 15th year, the IA 50 highlights experienced and emerging fund managers committed to delivering measurable impact alongside financial returns. The IA 50 serves as a publicly available database for investors and advisors seeking impact-focused private market managers. In 2026, fund managers across the IA 50 represent approximately $202 billion in combined assets under management, reflecting the continued scale of the...

Reviews Bempedoic Acid as Therapeutic Option for Diverse Patient Populations in Need of Alternatives to Statins in Cardiovascular Risk Management ANN ARBOR, Mich., March 17, 2026 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that two abstracts have been accepted for presentation in moderated poster sessions at the upcoming American College of Cardiology’s 2026 Annual Scientific Session (ACC.26) taking place March 28-30, 2026 in New Orleans, LA. “ACC.26 provides an important platform to share new insights from the CLEAR Outcomes trial among an audience of the world’s leading cardiologists,” said Sheldon Koenig, Chief Executive Officer of Esperion. “These analyses deepen our understanding of cardiovascular risk reduction in patients with other co-morbidities who are often underrepresented in traditional studies and reinforce...

VANCOUVER, British Columbia, March 17, 2026 (GLOBE NEWSWIRE) — Greenridge Exploration Inc. (“Greenridge” or the “Company”) (CSE: GXP | FRA: HW3 | OTCQB: GXPLF), is pleased to announce that it has filed a technical report (the “Report”) dated January 15, 2026, with an effective date of January 25, 2026, entitled “Technical Report For The Carpenter Lake Property, South Central Athabasca Basin, Northern Saskatchewan, Canada” prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”) on the Carpenter Lake Uranium Project (“Carpenter Lake” or the “Project”). The Report was authored by independent Qualified Person Kenneth Wheatley, P. Geo., M.Sc., of Rock U Consulting. The Report is available on SEDAR+ at www.sedarplus.ca and is published on Greenridge’s website at www.greenridge-exploration.com. Statement...

ORLANDO, Fla., March 17, 2026 (GLOBE NEWSWIRE) — Abacus Global Management, Inc. (“Abacus” or the “Company”) (NYSE: ABX), a leader in the alternative asset management industry, today announced its participation in the 38th Annual Roth Conference, taking place at the Ritz-Carlton in Laguna Niguel, CA on March 23-24, 2026. Members of Abacus management, including Chief Financial Officer Bill McCauley, Chief Capital Officer Elena Plesco, and Managing Director of Investor Relations David Jackson will be available for one-on-one and small-group investor meetings throughout the conference. To request a meeting with Abacus management, please contact your Roth representative, or email the Company’s Investor Relations team at ir@abacusgm.com. About AbacusAbacus Global Management (NYSE: ABX) is a leading financial services...

Oak Ridge, TN, March 17, 2026 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces its participation as an exhibitor at the American College of Cardiology (ACC.26) Annual Scientific Session in New Orleans, LA, March 28–30, 2026. Daxor will showcase its new, rapid, portable Blood Volume Analyzer (BVA). As the only FDA-cleared diagnostic providing greater than 95% accurate, direct quantification of a patient’s total blood, plasma, and red cell volume, the BVA replaces subjective guesswork with definitive data. This precision is a critical benefit of BVA, particularly for health systems navigating the $3.5 billion annual Medicare burden of heart failure readmissions in the United States. “The most expensive patient is the one who comes back,” said Michael Feldschuh,...

 Upfront cash fee with total value of $7.0 million, comprised of a $3.5 million cash payment and $3.5 million in-kind payment in the form of a transferable equity interest in licensee Initiation of Phase 1 clinical study in China by licensee expected in the first half of 2027 HCW Biologics has “free” option to reclaim the rights to the Americas territory MIRAMAR, Fla., March 17, 2026 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a U.S.-based commercial- and clinical-stage biopharmaceutical company focused on supporting or developing novel fusion immunotherapies to treat autoimmune diseases, cancer, and senescence-associated dysplasia, announced the receipt of full payment of the upfront license fee with a value of $7.0 million from its licensee, Beijing Trimmune Biotech Co., Ltd. (“Trimmune”). Trimmune is...